Loading...
OTCM
RNUGF
Market cap24kUSD
Jun 27, Last price  
0.00
Name

ReNeuron Group PLC

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.94%
Rev. gr., 5y
65.26%
Revenues
530k
+31.51%
1,0003,0009,00049,00027,00093,00031,00029,00040,00017,00022,00030,00029,00046,00043,00049,0006,065,000257,000403,000530,000
Net income
-5m
L-44.18%
-813,000-3,214,000-6,369,000-5,249,000-6,572,000-3,667,000-5,850,000-6,148,000-6,229,000-6,345,000-7,066,000-8,906,000-11,354,000-15,573,000-17,615,000-14,292,000-11,412,000-11,347,000-9,689,000-5,408,000
CFO
-7m
L+0.99%
-2,790,000-2,786,000-4,666,000-5,529,000-6,079,000-4,401,000-2,629,000-5,148,000-5,786,000-6,022,000-6,004,000-8,245,000-11,920,000-12,636,000-14,887,000-11,992,000-14,304,000-6,052,000-7,411,000-7,484,000

Profile

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
URL
https://www.reneuron.com/
IPO date
Aug 12, 2005
Employees
26
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
530
31.51%
Cost of revenue
10,057
Unusual Expense (Income)
NOPBT
(9,527)
NOPBT Margin
Operating Taxes
(1,249)
Tax Rate
NOPAT
(8,278)
Net income
(5,408)
-44.18%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,000
BB yield
Debt
Debt current
153
Long-term debt
689
Deferred revenue
Other long-term liabilities
Net debt
(6,311)
Cash flow
Cash from operating activities
(7,484)
CAPEX
(220)
Cash from investing activities
4,911
Cash from financing activities
(147)
FCF
(8,238)
Balance
Cash
7,153
Long term investments
Excess cash
7,126
Stockholders' equity
(111,091)
Invested Capital
116,473
ROIC
ROCE
EV
Common stock shares outstanding
57,126
Price
Market cap
EV
EBITDA
(9,260)
EV/EBITDA
Interest
20
Interest/NOPBT